Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

J Clin Oncol. 2005 May 1;23(13):2900-2. doi: 10.1200/JCO.2005.05.827.

Authors

Michael S Ewer¹, Scott M Lippman

Affiliation

¹ Departments of Cardiology and Clinical Cancer Prevention and Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

PMID: 15860848
DOI: 10.1200/JCO.2005.05.827

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Heart / drug effects*
Heart Diseases / chemically induced*
Heart Diseases / classification*
Heart Diseases / diagnosis
Humans
Neoplasms / drug therapy
Prognosis
Receptor, ErbB-2 / analysis

Substances

Antineoplastic Agents
Receptor, ErbB-2